Based on their distinct SE signatures, three out of the four identified SE subtypes were characterized by ADRN specific signatures that matched NB tumor samples from different clinical groups: MYCN-amplified high-risk (MYCNSE), MYCN non-amplified high-risk (MNA-HRSE), and MYCN non-amplified low-risk (MNA-LRSE). Here, MYCN is linked to neuroblastoma.